

02/10/00
Jc685 U.S. PTO

Please type a plus sign (+) inside this box → ☐

Approved for use through 09/30/2000 OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

| | | |
|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|----------------------------|
| UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 C.F.R. § 1.53(b)) | Attorney Docket No | UNME-0070-1 |
| | First Inventor or Application Identifier | Sklar et al. |
| | Title | FLOW CYTOMETRY FOR HIGH... |
| | Express Mail Label No | |

| | | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents | | ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231 | |
| 1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) | 5. <input type="checkbox"/> Microfiche Computer Program (Appendix) | ACCOMPANYING APPLICATION PARTS 7. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s)) 8. <input type="checkbox"/> 37 C.F.R. § 73(b) Statement <input checked="" type="checkbox"/> Power of Attorney (when there is an assignee) 9. <input type="checkbox"/> English Translation Document (if applicable) 10. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations 11. <input type="checkbox"/> Preliminary Amendment 12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 13. <input checked="" type="checkbox"/> * Small Entity Statement filed in prior application, Status still proper and desired (PTO/SB/09-12) 14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 15. <input checked="" type="checkbox"/> Other. Associate Power of Attorney, EDC Sheet | |
| 2. <input checked="" type="checkbox"/> Specification [Total Pages 24] - Descriptive title of the invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the invention - Brief Summary of the invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure | 6. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies | | |
| 3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 2] | | | |
| 4. <input type="checkbox"/> Oath or Declaration [Total Pages 2] a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed) c. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b) | | | |
| * NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28) | | | |


16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____ / _____

Prior application information Examiner _____ Group / Art Unit _____


For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label  or ☐ Correspondence address below


(Insert Customer Number or Bar Code label here) 22506

| | | | | | |
|---------|------------------------|-----------|--------------|----------|--------------|
| Name | Jagtiani & Associates | | | | |
| Address | 10379-B Democracy Lane | | | | |
| City | Fairfax | State | Virginia | Zip Code | 22030 |
| Country | U.S.A. | Telephone | 703-591-2664 | Fax | 703-591-5907 |

| | | | |
|-------------------|-------------------------------------------------------------------------------------|-----------------------------------|----------|
| Name (Print/Type) | K. Jagtiani | Registration No. (Attorney/Agent) | 35,205 |
| Signature |  | Date | 02-10-00 |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

| | |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Full Name | <input type="checkbox"/> Individual <input type="checkbox"/> Small Business Concern <input type="checkbox"/> Nonprofit Organization |
| Address | |

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Annabelle D. Quintana Associate University Counsel University of Los Angeles Patent Administration Office Hobson Hall, Room 357 500 University Ave., Los Angeles, CA 90032 | 1.5 10/24/92  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|

| Variable | Mean | SD | Min | Max |
|---------------------|-------------|-----------|-----|-----|
| Age | 38.5 | 12.5 | 18 | 65 |
| Gender | Male | Female | | |
| Marital Status | Married | Single | | |
| Education | High School | College | | |
| Occupation | Manager | Worker | | |
| Income | \$30,000 | \$40,000 | | |
| Health Status | Good | Fair | | |
| Exercise Frequency | Weekly | Monthly | | |
| Stress Level | Low | High | | |
| Sleep Quality | Good | Poor | | |
| Dietary Habits | Healthy | Unhealthy | | |
| Alcohol Consumption | Occasional | Frequent | | |
| Tobacco Use | Non-user | User | | |
| Family Size | 2 | 3 | | |
| Home Ownership | Owner | Renter | | |
| Commute Time | 30 min | 45 min | | |
| Work Hours | 40 hrs | 50 hrs | | |
| Job Satisfaction | High | Low | | |
| Life Satisfaction | High | Low | | |
| Overall Well-being | Good | Fair | | |

Correspondence Customer Number ::
Name Line One :: Ajay A. Jagtiani
Name Line Two :: Jagtiani & Associates
Address Line One :: 10379-B Democracy Lane
Address Line Two ::
City :: Fairfax
State/Province :: Virginia
Country :: United States
Postal or Zip Code :: 22030
Telephone :: (703) 591-2664
Fax :: (703) 591-5907
E-Mail :: patents@idsonline.com

Correspondence Customer Number ::
Name Line One :: Ajay A. Jagtiani
Name Line Two :: Jagtiani & Associates
Address Line One :: 10379-B Democracy Lane
Address Line Two ::
City :: Fairfax
State/Province :: Virginia
Country :: United States
Postal or Zip Code :: 22030
Telephone :: (703) 591-2664
Fax :: (703) 591-5907
E-Mail :: patents@idsonline.com

Application Information

Title Line One :: FLOW CYTOMETRY FOR HIGH THROUGHPUT SCREENING
Total Drawing Sheets :: 2
Formal Drawings :: Y
Application Type :: Utility
Docket Number :: UNME-0070-1
Licensed - U S Government Agency ::
Contract Number ::
Grant Number ::
Secrecy Order in Parent Application ::

Representative Information

Representative Customer Number ::
Registration Number One :: 35,205
Registration Number Two :: 33,057
Registration Number Three: 43,023
Continuity Information

This application is a ::
> Application One ::
Filing Date ::
Patent Number ::
which is a ::
>> Application Two ::
Filing Date ::
Patent Number ::

Prior Foreign Applications

Foreign Application One ::
Filing Date ::
Country ::
Priority Claimed ::

000T20" E49T0560

Application for

United States Letters Patent

of

Larry A. Sklar
Bruce S. Edwards
Frederick W. Kuckuck

for

FLOW CYTOMETRY FOR HIGH THROUGHPUT SCREENING

FLOW CYTOMETRY FOR HIGH THROUGHPUT SCREENING

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application makes reference to co-pending U.S. Provisional Patent Application No. 60/156,946, entitled "Flow Cytometry Real-Time Analysis of Molecular Interactions," filed November 9, 1999. The entire contents and disclosure of this application is hereby incorporated by reference.

GOVERNMENT INTEREST STATEMENT

10 This invention is made with government support under contract number NIH 1R24 GM 60799 (Project Number 3). The government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

Field of the Invention

15 The present invention relates to a flow cytometry apparatus.

Description of the Prior Art

20 Flow cytometry is used to characterize cells and particles by making measurements on each at rates up to thousands of events per second. The measurement consists of simultaneous detection of the light scatter and fluorescence associated with each event. Commonly, the fluorescence characterizes the expression of cell surface molecules or intracellular markers sensitive to cellular responses to drug molecules.

25 The technique often permits homogeneous analysis such that cell associated

fluorescence can often be measured in a background of free fluorescent indicator. The technique often permits individual particles to be sorted from one another.

However, a deficiency with conventional flow cytometry is that it does not allow for the analysis of multiple samples consisting of multiple cells or particles in a rapid manner, a fact that has limited the uses of flow cytometry in drug discovery. For example, the industrial standard for high throughput drug discovery is 100,000 samples per day. Because of its low throughput, flow cytometry has generally not been considered applicable to high throughput screening in drug discovery.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide a flow cytometry apparatus that meets the needs of high throughput screening.

According to one aspect of the present invention, there is provided a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles.

According to a second aspect of the present invention, there is provided a method for analyzing a plurality of samples comprising: moving a plurality of samples comprising particles into a fluid flow stream; separating adjacent ones of the plurality of samples from each other in the fluid flow stream by a separation gas; and selectively analyzing each of the plurality of samples for the particles.

Other objects and features of the present invention will be apparent from the following detailed description of the preferred embodiment.

5

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be described in conjunction with the accompanying drawings, in which:

10

Figure 1A is a schematic view of a flow cytometry apparatus constructed in accordance with a preferred embodiment of the invention;

Figure 1B is a cross-sectional schematic view of immediately adjacent samples in a tube of the flow cytometry apparatus of Figure 1A;

15

Figure 1C is a cross-sectional schematic view of buffer fluid separated adjacent samples in a tube of the flow cytometry apparatus of Figure 1A;

20

Figure 2A illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using .02 inches inner diameter PharMed TM tubing in terms of a graph of Forward Scatter vs. Side Scatter;

25

Figure 2B illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using .02 inches inner diameter PharMed TM tubing in terms of a graph of Fluorescence vs. Time (1024 channels = 60 seconds);

30

Figure 3A illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using Tygon TM PVC tubing S-54-HL in terms of a graph of Forward Scatter vs. Side Scatter;

Figure 3B illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using Tygon TM PVC tubing S-54-HL in terms of a graph of Fluorescence vs. Time (1024 channels = 60 seconds).

5

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

It is advantageous to define several terms before describing the invention. It should be appreciated that the following definitions are used throughout this application.

10

Definitions

Where the definition of terms departs from the commonly used meaning of the term, applicant intends to utilize the definitions provided below, unless specifically indicated.

15

For the purposes of the present invention, the term “particles” refers to any particles that may be detected using a flow cytometry apparatus.

For the purposes of the present invention, the term “biomaterial” refers to any organic material obtained from an organism, either living or dead. The term “biomaterial” also refers to any synthesized biological material such as synthesized oligonucleotides, synthesized polypeptides, *etc.* The synthesized biological material may be a synthetic version of a naturally occurring biological material or a non-naturally occurring biological made from portions of naturally occurring biological materials, such as a fusion protein, or two biological materials that have been bound together, such as an oligonucleotide, such as DNA or RNA, bound to a peptide, either covalently or non-covalently, that the oligonucleotide does not normally bind to in nature.

20

25

For the purposes of the present invention, the term “oligonucleotide” refers to any oligonucleotide, including double and single-stranded DNA, RNA, PNAs (peptide

30

nucleic acids) and any sequence of nucleic acids, either natural or synthetic, derivatized or underivatized.

For the purposes of the present invention the term “peptide” refers to all types of peptides and conjugated peptides including: peptides, proteins, polypeptides, protein sequences, amino acid sequences, denatured proteins, antigens, oncogenes and portions of oncogenes.

For the purposes of the present invention, the term “organism” refers not only to animals, plants, bacteria, viruses, *etc.* but also to cell cultures, reproduced oligonucleotides, *etc.* made from organic material obtained from animals, plants, bacteria, viruses, *etc.*

For the purposes of the present invention, the term “source well” refers to any well on a well plate, whether or not the source well contains a sample. For the purposes of the present invention, the term “sample source well” refers to a source well containing a sample.

For the purposes of the present invention, the term “sample” refers to a fluid solution or suspension containing particles to be analyzed using a method and/or apparatus of the present invention. The particles to be analyzed in a sample may be tagged, such as with a fluorescent tag. The particles to be analyzed may also be bound to a bead, a receptor, or other useful protein or polypeptide, or may just be present as free particles, such as particles found naturally in a cell lysate, purified particles from a cell lysate, particles from a tissue culture, *etc.* The sample may include chemicals, either organic or inorganic, used to produce a reaction with the particles to be analyzed. When the particles to be analyzed are biomaterials, drugs may be added to the samples to cause a reaction or response in the biomaterial particles. The chemicals, drugs or other additives may be added to and mixed with the samples when the samples are in

sample source wells or the chemicals, drugs or other additives may be added to the samples in the fluid flow stream after the samples have been intaken by the autosampler.

For the purposes of the present invention, the term “adjacent samples” refers to two samples in a fluid flow stream that are separated from each other by a separation gas, such as an air bubble. For the purposes of the present invention, the term “immediately adjacent samples” refers to adjacent samples that are only separated from each other by a separation gas. For the purposes of the present invention, “buffer fluid separated adjacent samples” refers to adjacent samples that are separated from each other by two separation gas bubbles and a buffer fluid, with the buffer fluid being located between the two separation gas bubbles.

For the purposes of the present invention, the term “separation gas” refers to any gas such as air, an inert gas, or fluid *etc.* that can be used to form a gas bubble or immiscible fluid between adjacent samples or between a sample and a buffer fluid. An immiscible fluid is a fluid that will not substantially mix with and contaminate a sample.

For the purposes of the present invention, the term “buffer fluid” refers to a fluid that is substantially free of the particles to be detected by the apparatus and method of the present invention.

For the purposes of the present invention, the term “drug” refers to any type of substance that is commonly considered a drug. For the purposes of the present invention, a drug may be a substance that acts on the central nervous system of an individual, e.g. a narcotic, hallucinogen, barbiturate, or a psychotropic drug. For the purposes of the present invention, a drug may also be a substance that kills or inactivates disease-causing infectious organisms. In addition, for the purposes of the present invention, a drug may be a substance that affects the activity of a specific cell, bodily organ or function. A drug may be an organic or inorganic chemical, a biomaterial, *etc.*

For the purposes of the present invention, the term “plurality” refers to two or more of anything, such as a plurality of samples.

For the purposes of the present invention, the term “homogenous” refers to a plurality of identical samples. The term “homogenous” also refers to a plurality of samples that are indistinguishable with respect to a particular property being measured by an apparatus or a method of the present invention.

For the purposes of the present invention, the term “heterogeneous” refers to a plurality of samples in a fluid flow stream in which there are at least two different types of samples in the fluid flow stream. One way a heterogeneous plurality of samples in a fluid flow stream of the present invention may be obtained is by intaking different samples from different source wells in a well plate. Another way of obtaining a heterogeneous plurality of samples is by intaking different samples from identical source wells at various time points where a reaction or a series of reactions is or had been occurring.

For the purposes of the present invention, the term “fluid flow stream” refers to a stream of fluid samples, separated by one or more bubbles of a separation gas and/or one or more portions of a buffer fluid.

For the purposes of the present invention, the term “fluid flow path” refers to device such as a tube, channel, *etc.* through which a fluid flow stream flows. A fluid flow path may be composed of several separate devices, such as a number of connected or joined pieces of tubing or a single piece of tubing, alone or in combination with channels or other different devices.

For the purposes of the present invention, the term “high speed multi-sample tube” refers to any tube that may be used with a peristaltic pump that has compression characteristics that allow a peristaltic pump to move samples separated by a separation gas through the tube at a speed of at least 6 samples per minute without causing adjacent

samples to mix with each other. An example of such a tube is a polyvinylchloride (PVC) tube having an inner diameter of about 0.01 to 0.03 inches and a wall thickness of about 0.01 to 0.03 inches. A particularly preferred tube is a PVC tube having an inner diameter of about 0.02 inches and a wall thickness of about 0.02 inches.

5

Description

There have been several efforts at automated sample handling in flow cytometry. For, example, both Coulter Instrument Co. and Becton-Dickinson have sold sample handling systems that use carousels to handle samples from standard sized tubes. These systems typically intake samples at a rate of ~ 1 tube of sample per minute.

There has also been some effort to intake samples from 96 well plates. For example at the ISAC meeting in 1998 at Colorado Springs, Coulter Instrument Co. showed a TECAN sampling system for 96 well plates that sampled at about the rate of 3 samples per 2 minutes. Becton-Dickinson is presently developing a system with similar characteristics. Luminex Corp. (Austin, TX) is developing a system that samples at rates of 2-4 samples/minute. It puts a multi-well plate on a movable stage that brings it into position with a syringe controlled sample line.

Other groups have also used valves and syringes in flow cytometry, most notably, the "flow injection" group, Lindberg *et al.* at University of Washington. One group, Zhao *et al.* at the University of Minnesota, has recently reported the use of air bubbles in flow cytometry to separate samples. However, in none of the processes described above is there any mention of throughput speed (samples/minute). A group at the University of New Mexico has used plug flow cytometry and achieved sampling rates of at least 6 samples per minute, see U.S. Patent Application No. 09/330,259, the entire disclosure and contents of which is hereby incorporated by reference. Furthermore, in the published descriptions of these processes, the problems with bubbles disrupting flow cytometry were also pointed out.

15 In an alternative embodiment of the present invention using the flow cytometry apparatus of Figure 1A, some of the source wells on the well plate of the apparatus illustrated in Figure 1A may contain a buffer solution to allow for the formation of buffer fluid separated adjacent samples in a tube through which samples pass. When this is the case, after each sample is picked up by the probe, the probe intakes air, then is
20 lowered into a source well containing buffer solution, then the probe intakes air again, and then the probe intakes a second sample. This sequence may then be repeated for samples which the probe subsequently intakes. Figure 1C shows how two buffer fluid separated adjacent samples 140 and 142 are separated from each other by buffer fluid 144 and two air bubbles 146 and 148 in tube 114. When samples 140 and 142 pass
25 through laser interrogation point 122, the particles in the samples are sensed by the flow cytometer due to the fluorescent tag on the particles. In contrast, when buffer fluid 144, and air bubbles 146 and 148 pass through laser interrogation point 122, no particles are sensed. Therefore, a graph of the data points of fluorescence sensed versus time for a series of samples analyzed using the flow cytometer of the present invention will form
30 distinct groups, each aligned with the time that a sample containing particles passes through the laser interrogation point. In order to detect the presence of two or more

different types of samples, each of the two or more different types of samples may be tagged with different fluorescence tags or different amounts of a single tag. In such a case, the groupings of data points will vary vertically on a fluorescence versus time graph, depending on which type of sample is being sensed. As with the case of sensing a single type of sample, each sensed sample will exhibit a group of data points aligned with the time that the sample passes through the laser interrogation point.

Alternatively, buffer fluid separated adjacent samples may be formed by providing a reservoir of buffer fluid in or attached to the autosampler to inject buffer fluid into the tube for the fluid flow stream. In this case, after each sample is picked up by the probe, the probe intakes air, then buffer fluid is injected into the tube for the fluid flow stream, then the probe intakes air again, and then the probe intakes a second sample. This sequence may then be repeated for subsequent samples to be separated by a buffer fluid.

The present invention is compatible with relatively inexpensive commercial well plates for use with autosamplers from 96 well plates to 384 well plates to at least as many as 1536 well plates. The source wells of the present invention may be all filled with samples and/or buffer fluids, or some may be left empty. When there are a plurality of different types of samples in the source wells of a well plate, the sample types may be arranged in the order in which they are taken up by the probe, or the sample types may be arranged in any other convenient arrangement. For example, all of the source wells in a one row of source wells may contain one sample type and all of the source wells of a second row may contain a second sample type.

The source wells may be made any conventional shape used for source wells in a well plate for an autosampler. Preferably, when small amounts of sample are used in each source well, the source wells are conical in shape, as illustrated in Figure 1A, to allow even the smallest amounts of sample to be withdrawn by the probe or to allow the particles to concentrate in the bottom of the well. The use of a well plate with conical source wells reduces the problems associated with the settling of particles to the bottom

of the well prior to being intaken by the probe. An alternative means to circumvent particle settling would be to sample from wells in an inverted plate given an appropriate well dimensions that will permit sample retention in the well (e.g. by capillary forces) when the plate is in this position.

5 The autosampler of the present invention may be any conventional autosampler suitable for intaking samples from a well plate. A preferred type of autosampler is the Gilson 215 liquid manager.

10 The use of automation in plate delivery and retrieval for the autosampler may allow automation of the overall screening process.

15 One preferred probe for the present invention is a .01 inch ID, 1/15 inch OD stainless steel needle compatible with HPLC ferrule fittings. A Gilson interface module for bidirectional communication between an MS DOS computer and a probe
20 manipulating arm and peristaltic pump. Software designed using commercial languages, such as Microsoft Visual C++, may be used to control the speed and distance of probe motions in all 3 dimensions, the sensing of probe contact with liquid in a source well to assure reproducible sample volumes, and the speed of the peristaltic pump. A computer or other known device may be used to control the autosampler to
25 regulate sample size and bubble size by varying the time that the probe is in a source well or above a source well. Also, various sample handlers and sampler handling systems that may be useful in the apparatus and method of the present invention are well known in the art. One example of an integrated handler and programmable station is the Beckman 1000 Laboratory Workstation TM robotic which may be adapted for use in the
30 apparatus or method of the present invention.

 In order to reduce carryover, the probe may have a conical tip. Use of silicone or other hydrophobic agent to coat the tip of the sampling probe may also be helpful to minimize sample carryover. Alternatively, the entire probe may be made of a
30 hydrophobic material to reduce carryover. Suitable hydrophobic materials for used in the coating or for making the entire hydrophobic probe include: Teflon®

(poly(tetrafluoroethylene) (PTFE)), Kynar ® (polyvinylidene fluoride), Tefzel ® (ethylene-tetrafluoroethylene copolymer), tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer resin (PFA), a tetrafluoroethylene-hexafluoropropylene copolymer (EFP), polyether ether ketone (PEEK), *etc.*

5

In order to reduce sample carryover, a jet of gas, such as air, may be sprayed on the tip of the autosampler probe. The source of the jet of gas may be mounted either on the autosampler or near the autosampler. Another way to reduce sample carryover is to use a rinsing device that may be attached to the autosampler or be otherwise mounted on or near the flow cytometry apparatus of the present invention to rinse the autosampler probe between intakes of sample and/or buffer solution. The rinsing fluid may be water, a mild detergent, or a solvent, such as a solvent in which each of the particles in one or more of the samples is dissolved. When the particles are merely suspended in a suspension fluid, the rinsing fluid may be the same as the suspension fluid. The use of an autosampler with a sensing probe tip may improve the efficiency of sample uptake and performance by reducing carryover and ensuring reproducible sample volumes.

Various conventional peristaltic pumps may be used with the flow cytometry apparatus of the present invention. A preferred peristaltic pump is Gilson Minipuls 3. Preferably, a peristaltic pump of the present invention is operated in a manner that reduces pulsatile flow, thereby improving the sample characteristics in the flow cytometer. For example, a tubing length greater than 20 inches between pump and flow cytometer may be used or a linear peristaltic pump such as the Digicare LP5100 may be used to improve the sample characteristics.

25

Various types of tubing may be used for the fluid flow path of the present invention, as long as the tubing may function as high speed multi-sample tubing. When thin walled PVC (polyvinyl chloride) tubing is used as the tubing for the present invention, carryover between samples is substantially reduced compared to conventional peristaltic tubing. Preferably, the fluid flow path of the present invention is a single length of tubing without junctions. Such a single length of tubing reduces the breakup

30

of bubbles and improves the performance in sample separation. A preferred type of high speed multi-sample tubing for use with the present invention is 0.01 to 0.03 inch inner diameter PVC tubing having a wall thickness of 0.01 to 0.03 inches. A particularly preferred tubing is 0.02 inch inner diameter PVC tubing having a wall thickness of 0.02 inch.

Various types of flow cytometers may be used with the flow cytometry apparatus of the present invention. Preferred types of flow cytometers are described in U.S. Patent Nos. 5,895,764; 5,824,269; 5,395,588; 4,661,913; the entire contents and disclosures of which are hereby incorporated by reference. In the flow cytometer, samples may be sorted on a particle by particle basis using known methods. The flow cytometer may use software gating by light scatter to reduce the "noise" in the flow cytometer introduced by the periodic appearance of bubbles. The use of the real-time software in conjunction with flow cytometer controlling software may allow the samples from a given source well to be re-checked during sampling and data analysis to prove that "hits" from neighboring source wells do not arise from cross-contamination.

On-line data analysis may be used in the flow cytometer to compare data between well plates and facilitate overall utility of the data in conjunction with automation. Operation of the flow cytometer at higher pressure generally increases the sample flow rate and may, in some circumstances yield a higher throughput. Also, operation of the flow cytometer with increased time resolution in data software may allow resolution of samples at higher throughput rates.

Both peristaltic pumps and air bubbles have been used in a variety of detection devices with flowing samples. For example, bubbles are commonly used in clinical instruments to separate samples and the peristaltic pumps to move fluids. However, in flow cytometry there is specific teaching against air bubbles with the idea that, optimally, the bubbles should be removed from the sample prior to injection into the flow cytometer.

Using the flow cytometry apparatus of the present invention, it has already been possible to move and analyze at least 6 samples per minute. Preferably, the flow cytometry apparatus may be capable of moving and analyzing 60 samples per minute, even more preferably 120 samples per minute, and yet even more preferably 240 samples per minute.

Among the advantages of the flow cytometer apparatus of the present invention is that it allows rapid sampling of small volumes of sample. For example, a sample drawn into the fluid stream tubing at 10 rpm and flowing at a rate of ~3 ul/sec requires less than a 2 ul sample.

The throughput of the flow cytometry apparatus of the present invention tends to be more affected by the behavior of the autosampler rather than the characteristics of the peristaltic pump, the tubing or the flow cytometer. Thus, to the extent that an autosampler can move more rapidly from source well to source well, higher throughputs are achieved. Improved accuracy in volume intake/delivery by the autosampler leads to smaller sample volumes and improved throughputs.

EXAMPLE

Using a flow cytometer apparatus set-up similar to that shown in Figure 1A, commercial peristaltic tubing with thick walls (PharMed TM; 0.02 inch inner diameter, 3.69 mm outer diameter, polypropylene elastomer) was compared with another type (0.02 inch inner and 0.06 inch outer diameter Tygon Microbore TM, formulation S-54-HL) that had thin walls and was considerably stiffer. Figures 2A and 2B illustrate the flow cytometer results using the PharMed TM tubing to move samples 202, 206, 210, and 214 of Coulter Flow-Check beads having a proprietary fluorochrome as a fluorescence tag and four samples 204, 208, 212, and 216 of Flow Cytometry Standards Corporation having fluorescein as a fluorescence tag. Figure 2A is a graph of Forward Scatter vs. Side Scatter with a gate around the particles aligned in the laser beam of the

flow cytometer. Figure 2B is a graph of Fluorescence vs. Time (1024 channels = 60 seconds). The samples in Figure 2 are moved through the tubing using a peristaltic pump operating at 10 RPM. Figures 3A and 3B illustrate the flow cytometer results using the PVC tubing to move samples 302, 306, 310, and 314 of Coulter Flow-Check beads having a proprietary fluorochrome as a fluorescence tag and four samples 304, 308, 312, and 316 of Flow Cytometry Standards Corporation beads having fluorescein as a fluorescence tag. Figure 3A is a graph of Forward Scatter vs. Side Scatter with a gate around the particles aligned in the laser beam of the flow cytometer. Figure 3B is a graph of Fluorescence vs. Time (1024 channels = 60 seconds). The samples in Figure 3 are moved through the tubing using a peristaltic pump operating at 10 RPM. As can be seen in Figure 2B and Figure 3B, the grouping of sample data points in Figure 2B exhibit 27% carryover (particles between samples) compared to the groupings of sample data points in Figure 3B that exhibit 5% carryover (particles between samples), indicating that the PVC tubing preserves the integrity of samples better than the PharMed TM tubing does.

Although the present invention has been fully described in conjunction with the preferred embodiments thereof with reference to the accompanying drawings, it is to be understood that various changes and modifications may be apparent to those skilled in the art. Such changes and modifications are to be understood as included within the scope of the present invention as defined by the appended claims, unless they depart therefrom.

[illegible]

6. The flow cytometry apparatus of claim 5, wherein said probe comprises a hydrophobic material.
7. The flow cytometry apparatus of claim 5, wherein said probe is coated with a hydrophobic material.
8. The flow cytometry apparatus of claim 2, wherein said means for moving said plurality of samples further comprises a peristaltic pump.
9. The flow cytometry apparatus of claim 8, wherein a portion of said fluid flow stream passing through said peristaltic pump is contained within a high speed multi-sample tube.
10. The flow cytometry apparatus of claim 8, wherein said peristaltic pump is located along said fluid flow stream between said autosampler and said means for selectively analyzing said plurality of samples.
11. The flow cytometry apparatus of claim 10, further comprising a single length of tubing extending from said autosampler to said means for selectively analyzing said plurality of samples.

19. The flow cytometry apparatus of claim 18, wherein said biomaterials are fluorescently tagged.

20. The flow cytometry apparatus of claim 1, further comprising a well plate including said plurality of respective source wells.

21. The flow cytometry apparatus of claim 20, wherein said well plate includes at least 96 source wells.

22. The flow cytometry apparatus of claim 20, wherein said well plate includes at least 384 source wells.

23. The flow cytometry apparatus of claim 20, wherein said well plate includes at least 1536 source wells.

24. The flow cytometry apparatus of claim 20, wherein said well plate includes wells having a conical shape.

25. The flow cytometry apparatus of claim 20, wherein said well plate is mounted in an inverted position.

26. The flow cytometry apparatus of claim 1, further comprising a means for injecting a buffer fluid between adjacent samples in said fluid flow stream.

33. The method of claim 28, wherein at least 120 samples are selectively analyzed per minute.

34. The method of claim 28, wherein at least 240 samples are selectively analyzed per minute.

35. The method of claim 28, wherein said plurality of samples are homogenous.

36. The method of claim 28, wherein said plurality of samples are heterogeneous.

37. The method of claim 28, wherein said particles comprise biomaterials.

38. The method of claim 28, wherein said biomaterials are fluorescently tagged.

39. The method of claim 28, wherein said samples have a sample size ranging from at least about 0.1 to at least about 10 μ l.

40. The method of claim 28 wherein said samples flow in said fluid flow stream at a flow rate of at least about 0.1 to at least about 10 $\mu\text{l}/\text{sec}$.

41. The method of claim 28, further comprising injecting a buffer fluid between at least two adjacent samples in said fluid flow stream

42. The method of claim 28, by which said plurality of samples are sorted on a particle by particle basis in a flow cytometer.

43. The method of claim 28, further comprising mixing at least one of said plurality of samples with at least one drug.

44. The method of claim 43, wherein said at least one drug is mixed with said at least one of said plurality of samples in a sample source well.

45. The method of claim 43, wherein said at least one drug is mixed with said at least one of said plurality of samples in said fluid flow stream.

ABSTRACT OF THE DISCLOSURE

The present invention, provides a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles. The present invention also provides a flow cytometry method employing such an apparatus.

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 2A




Fig. 2B




Fig. 3A





Fig. 3B



As a below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name. I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention (Design, if applicable) entitled: **FLOW CYTOMETRY FOR HIGH THROUGHPUT SCREENING**; the specification of which (check one)

- I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims as amended by any amendment(s) referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37 Code of Federal Regulations, § 1.56(a). I hereby claim foreign priority benefits under Title 35 United States Code § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which the priority is claimed.

| NUMBER | COUNTRY | DAY/MONTH/YEAR FILED | PRIORITY CLAIMED |
|--------|---------|----------------------|----------------------------------------------------------|
| | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |

| APPLICATION NUMBER | FILING DATE | STATUS (Patented, Pending or Abandoned) |
|--------------------|-------------|-----------------------------------------|
| | | |
| | | |

POWER OF ATTORNEY: I/We hereby appoint as my (our) attorney(s), with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Ajay A. Jagann, Registration Number 35,265

Telephone calls to Ajay A Jagtiani
(703) 501-2004

| | | | |
|------------------------------------------------------------|--------------|----------------------------------------------------|--------------|
| Full Name of Additional Joint Inventor SEKLAR, Larry A. | | Citizenship United States | |
| Residence Address - Street 400 Aspen Avenue, NE | | Post Office Address Street 400 Aspen Avenue, NE | |
| City Albuquerque | | City Albuquerque | |
| State or Country New Mexico | Zip 87110 | State or Country New Mexico | Zip 87110 |
| DATE February 9 2000 | | SIGNATURE Larry A Seklar | |

DECLARATION FOR PATENT APPLICATION AND APPOINTMENT OF ATTORNEY

Page 2

| | |
|--------------------------------------------------------------------|---------------------------------------------------------|
| Full Name of Additional Joint Inventor EDWARDS, Bruce S. | Citizenship United States |
| Residence Address - Street 1407 Harvard Drive | Post Office Address Street 1407 Harvard Drive |
| City Albuquerque | City Albuquerque |
| State or Country New Mexico | State or Country New Mexico |
| Zip 87106 | Zip 87106 |
| DATE February 9, 2000 | SIGNATURE Bruce S. Edwards |

| | |
|-----------------------------------------------------------------|------------------------------------------------|
| Full Name of Additional Joint Inventor KUCKUCK, Frederick W. | Citizenship United States |
| Residence Address - Street 600 Grove Street | Post Office Address Street 600 Grove Street |
| City Albuquerque | City Albuquerque |
| State or Country New Mexico | State or Country New Mexico |
| Zip 87198 | Zip 87198 |
| DATE February 9, 2000 | SIGNATURE Frederick W. Kuckuck |

| | |
|----------------------------------------|----------------------------|
| Full Name of Additional Joint Inventor | Citizenship |
| Residence Address - Street | Post Office Address Street |
| City | City |
| State or Country Zip | State or Country Zip |
| DATE | SIGNATURE |

| | |
|----------------------------------------|----------------------------|
| Full Name of Additional Joint Inventor | Citizenship |
| Residence Address - Street | Post Office Address Street |
| City | City |
| State or Country Zip | State or Country Zip |
| DATE | SIGNATURE |

| Variable | Mean | Standard deviation | Minimum | Maximum |
|----------------------|------|--------------------|---------|---------|
| Age | 34.5 | 10.5 | 20 | 55 |
| Gender | 0.5 | 0.5 | 0 | 1 |
| Marital status | 0.5 | 0.5 | 0 | 1 |
| Education | 12.5 | 1.5 | 10 | 15 |
| Income | 1.5 | 0.5 | 1 | 2 |
| Health status | 0.5 | 0.5 | 0 | 1 |
| Smoking status | 0.5 | 0.5 | 0 | 1 |
| Alcohol consumption | 0.5 | 0.5 | 0 | 1 |
| Exercise frequency | 0.5 | 0.5 | 0 | 1 |
| Stress level | 0.5 | 0.5 | 0 | 1 |
| Work satisfaction | 0.5 | 0.5 | 0 | 1 |
| Life satisfaction | 0.5 | 0.5 | 0 | 1 |
| Overall health | 0.5 | 0.5 | 0 | 1 |
| Quality of life | 0.5 | 0.5 | 0 | 1 |
| Physical health | 0.5 | 0.5 | 0 | 1 |
| Mental health | 0.5 | 0.5 | 0 | 1 |
| Social health | 0.5 | 0.5 | 0 | 1 |
| Emotional health | 0.5 | 0.5 | 0 | 1 |
| Psychological health | 0.5 | 0.5 | 0 | 1 |
| Behavioral health | 0.5 | 0.5 | 0 | 1 |
| Environmental health | 0.5 | 0.5 | 0 | 1 |
| Community health | 0.5 | 0.5 | 0 | 1 |
| Public health | 0.5 | 0.5 | 0 | 1 |
| Global health | 0.5 | 0.5 | 0 | 1 |
| World health | 0.5 | 0.5 | 0 | 1 |
| Human health | 0.5 | 0.5 | 0 | 1 |
| Animal health | 0.5 | 0.5 | 0 | 1 |
| Plant health | 0.5 | 0.5 | 0 | 1 |
| Environmental health | 0.5 | 0.5 | 0 | 1 |
| Community health | 0.5 | 0.5 | 0 | 1 |
| Public health | 0.5 | 0.5 | 0 | 1 |
| Global health | 0.5 | 0.5 | 0 | 1 |
| World health | 0.5 | 0.5 | 0 | 1 |
| Human health | 0.5 | 0.5 | 0 | 1 |
| Animal health | 0.5 | 0.5 | 0 | 1 |
| Plant health | 0.5 | 0.5 | 0 | 1 |

